ECJ Competition – Agreements, decisions and concerted practices – Market for antidepressant medicinal products containing the active pharmaceutical ingredient citalopram – Concept of restriction of competition ‘by object’ – Potential competition – Generic medicinal products – Barriers to market entry resulting from the existence of patents – Agreements concluded between a patent holder and generic undertakings – Article 101(1) and (3) TFEU – Errors of law and of assessment – Obligation to state reasons – Rights of defence – Legal certainty – Fines
T-472/13, [2016] EUECJ T-472/13, ECLI:EU:T:2016:449
Bailii
European
European
Updated: 22 January 2022; Ref: scu.569060
